Contains Nonbinding Recommendations
4
which was superseded in November 2018 by the guidance, “Unique Device Identification: Policy
Regarding Compliance Dates for Class I and Unclassified Devices and Certain Devices
Requiring Direct Marking,”
and then subsequently superseded in July 2020 by the guidance
with the same title (hereafter referred to as “2020 UDI Compliance Policy Guidance”).
Throughout that time, FDA has been working with labelers on implementing UDI requirements
and addressing policy and technical issues. The prior versions of this guidance reflected our
belief that it was important to continue focusing our resources on addressing UDI
implementation issues and data quality for higher risk devices. In addition, as described in the
2020 UDI Compliance Policy Guidance, to the extent the policy articulated in that guidance
helped labelers remain focused on public health needs related to Coronavirus Disease 2019
(COVID-19), we believe it was further consistent with the public health.
As UDI implementation has progressed, FDA has gained further insight into the public health
benefits and potential burdens of UDI requirements for class I devices, which generally pose the
lowest risk. Many 510(k)-exempt class I devices are sold directly to consumers over-the-counter
in brick-and-mortar and/or online stores. For purposes of this guidance, we refer to these devices,
when they do not fall within one or more of the categories identified in section III.B.2, as
“consumer health products.” These class I devices are also typically labeled with a Universal
Product Code (UPC),
which is a barcode primarily used for scanning items at the point of sale.
The UPC is used to identify products to a very granular level—such as where in stores the
product is displayed, and whether the product has temporary promotional packaging—and the
UPC for the same version or model of a device can change frequently.
With respect to class I devices that are consumer health products, FDA believes that the entry of
UDI data into GUDID, especially given the frequent changes to the UPCs serving as the UDIs
for these devices, is burdensome to stakeholders. Further, FDA considered the public health
benefit of GUDID submission for consumer health products and the risks to public health if
GUDID submission is not provided for these devices. After reviewing available postmarket
information, such as medical device reports and recall data for class I devices, FDA has a better
understanding of the devices and device characteristics for which GUDID information is
particularly useful in evaluating and improving device safety throughout a product lifecycle, as
well as those for which GUDID information may be less important in this regard. Based on this
analysis, at this time, FDA does not intend to enforce the GUDID submission requirements under
21 CFR 830.300 for consumer health products.
requirements (21 CFR 801.18, 21 CFR 801.20, 21 CFR 801.50, and 21 CFR 830.300) prior to September 24, 2020,
and direct mark requirements (21 CFR 801.45) prior to September 24, 2022.
83 FR 55372 (Nov. 5, 2018). This previous version of the guidance retained the original compliance policy and
clarified FDA’s policy on direct marking requirements for certain non-sterile devices in inventory.
85 FR 39477 (Jul. 1, 2020). This previous version of the guidance stated that FDA did not intend to enforce
standard date formatting, UDI labeling, and GUDID data submission requirements under 21 CFR 801.18, 21 CFR
801.20, 21 CFR 801.50, and 21 CFR 830.300 for class I and unclassified devices, other than I/LS/LS devices, before
September 24, 2022.
For class I devices, the UDI Rule provides that the UPC may serve as the UDI (21 CFR 801.40(d)). As with the
production identifier exception for class I devices (21 CFR 801.30(d)), this option for a UPC was provided after
weighing the public health benefit against the burden on industry with respect to these lower risk devices.